Journal articlePreclinical

Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound

Alzheimer's research & therapy, 2017 Jun 27. Baazaoui N, Iqbal K.

Study type

Journal article

Subjects

Animal / preclinical (no Humans MeSH term)

Journal

Alzheimer's research & therapy

Published

2017 Jun 27

PubMed

PMID 28655344 ↗

DOI

10.1186/s13195-017-0273-7 ↗

Full text

Free on PubMed Central (PMC5488423) ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

P21 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

Administration, OralAlzheimer DiseaseAnimalsCiliary Neurotrophic FactorCognitionCognitive DysfunctionDendritesDose-Response Relationship, DrugMiceMice, Inbred C57BLMice, TransgenicNerve Growth Factors

Other papers on P21

Review · 2022

Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound

Journal article · 2021

Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction

Journal article · 2014

Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page